Daewoong Pharmaceutical announced on August 26 that it has been selected as a partner for Seoul's citizen blood sugar management initiative, 'Blood Sugar Catch 9988,' where it will provide continuous glucose monitoring (CGM) devices and lifestyle management services.
'Blood Sugar Catch 9988' targets 1,000 Seoul residents identified as pre-diabetic (with fasting blood sugar levels between 100 and 125 mg/dL) through metabolic syndrome screenings at public health centers. Participants can join the program by linking their screening results to Seoul's public health management platform, 'Wrist Doctor 9988.'
In July, the city publicly sought private partners and ultimately selected Daewoong Pharmaceutical.
Participants will wear a continuous glucose monitor for a set period, allowing them to track changes in their blood sugar levels and observe how their eating and exercise habits affect these fluctuations. By using the blood sugar-based metabolic health management platform 'Welda,' they can better understand their blood sugar data and apply it to lifestyle management.
'Welda' will present continuous glucose data in an easily understandable format, offering step-by-step guidance and related content to help users assess their eating and activity patterns and adopt healthier habits. Daewoong Pharmaceutical emphasized that connecting data to real lifestyle changes is the program's core objective.
Participants can purchase the glucose monitoring device and associated app services at a discount of over 45% off the regular price. Applications for participation will be accepted starting September 9 through the 'Wrist Doctor 9988' app. To qualify, individuals must have had a metabolic syndrome screening at a public health center within the last three years, with fasting blood sugar levels indicating pre-diabetes (100-125 mg/dL).
The city will establish a support system for participants in collaboration with health centers across 25 districts. Daewoong Pharmaceutical will provide training for health center staff, along with user guides and consultation materials.
Park Hyung-cheol, head of Daewoong Pharmaceutical's ETC Marketing Division, stated, "We will work closely with the city of Seoul and the 25 health centers to ensure that participants can connect their blood sugar data to healthy lifestyle habits, contributing effectively to the health improvement of Seoul residents."
Meanwhile, the number of diabetes patients continues to rise. According to data from the Korean Diabetes Association, approximately 5.33 million adults aged 30 and older were diagnosed with diabetes as of 2021-2022, while around 14.1 million were estimated to be pre-diabetic. Combined, these groups account for about 19.43 million individuals, or 56.6% of adults over 30.
'Blood Sugar Catch 9988' targets 1,000 Seoul residents identified as pre-diabetic (with fasting blood sugar levels between 100 and 125 mg/dL) through metabolic syndrome screenings at public health centers. Participants can join the program by linking their screening results to Seoul's public health management platform, 'Wrist Doctor 9988.'
In July, the city publicly sought private partners and ultimately selected Daewoong Pharmaceutical.
Participants will wear a continuous glucose monitor for a set period, allowing them to track changes in their blood sugar levels and observe how their eating and exercise habits affect these fluctuations. By using the blood sugar-based metabolic health management platform 'Welda,' they can better understand their blood sugar data and apply it to lifestyle management.
'Welda' will present continuous glucose data in an easily understandable format, offering step-by-step guidance and related content to help users assess their eating and activity patterns and adopt healthier habits. Daewoong Pharmaceutical emphasized that connecting data to real lifestyle changes is the program's core objective.
Participants can purchase the glucose monitoring device and associated app services at a discount of over 45% off the regular price. Applications for participation will be accepted starting September 9 through the 'Wrist Doctor 9988' app. To qualify, individuals must have had a metabolic syndrome screening at a public health center within the last three years, with fasting blood sugar levels indicating pre-diabetes (100-125 mg/dL).
The city will establish a support system for participants in collaboration with health centers across 25 districts. Daewoong Pharmaceutical will provide training for health center staff, along with user guides and consultation materials.
Park Hyung-cheol, head of Daewoong Pharmaceutical's ETC Marketing Division, stated, "We will work closely with the city of Seoul and the 25 health centers to ensure that participants can connect their blood sugar data to healthy lifestyle habits, contributing effectively to the health improvement of Seoul residents."
Meanwhile, the number of diabetes patients continues to rise. According to data from the Korean Diabetes Association, approximately 5.33 million adults aged 30 and older were diagnosed with diabetes as of 2021-2022, while around 14.1 million were estimated to be pre-diabetic. Combined, these groups account for about 19.43 million individuals, or 56.6% of adults over 30.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.